Advertisement

Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease

  • H. Yoshino
  • Y. Nakagawa-Hattori
  • T. Kondo
  • Y. Mizuno
Full Papers

Summary

Mitochondrial Complex I deficiencies have been described not only in the brain but also in the skeletal muscle and platelets in Parkinson's disease (PD). We report activities of Complex I, II, III, and IV in lymphocytes and platelets in 20 patients with PD and age-matched controls. A small but a significant decrease in the platelet Complex I activity was found in PD (9.14±1.86 units/mg protein) compared with that in the control (12.37±2.66 units/mg protein) (P=0.0002). The lymphocyte Complex I activity was about the same between PD and the control. The activity of Complex II was slightly diminished in both platelets and lymphocytes in PD. Rather small decrease in the platelet Complex I activity in PD may be clinically non-significant. But it may indicate the presence of a qualitatively similar abnormality in platelets as in the nigro-striatal neurons. The cause for decrease in the Complex II activity is unknown at this moment. Further studies seem necessary.

Keywords

Parkinson's disease pathogenesis biochemistry mitochondria Complex I 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bindoff LA, Birch-Machin M, Cartlidge NEF, Parker WD Jr, Turnbull DM (1989) Mitochondrial function in Parkinson's disease. Lancet i: 49Google Scholar
  2. DiMonte D, Jewell SA, Ekstrom G, Sandy MS, Smith MT (1986) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion is isolated hepatocytes. Biochem Biophys Res Commun 137: 310–315Google Scholar
  3. Heikkila RE, Nicklas WJ, Vyas I, Duvoisin RC (1985) Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Neurosci Lett 62: 389–394Google Scholar
  4. Ikebe S, Tanaka M, Ohno K, Sato W, Hattori K, Kondo T, Mizuno Y, Ozawa T (1990) Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence. Biochem Biophys Res Commun 170: 1044–1048Google Scholar
  5. Linnane AW, Marzuki S, Ozawa T, Tanaka M (1989) Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases. Lancet i: 642–645Google Scholar
  6. Mizuno Y, Sone N, Saitoh T (1986) Dopaminergic neurotoxins, MPTP and MPP+, inhibit activity of mitochondrial NADH-ubiquinone oxidoreductase. Proc Jpn Acad Ser B 62: 261–263Google Scholar
  7. Mizuno Y, Saitoh T, Sone N (1987a) Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity by 1-methyl-4-phenylpyridinium ion. Biochem Biophys Res Commun 143: 294–299Google Scholar
  8. Mizuno Y, Saitoh T, Sone N (1987b) Inhibition of mitochondrial alpha-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion. Biochem Biophys Res Commun 143: 971–976Google Scholar
  9. Mizuno Y, Sone N, Saitoh T (1987c) Effects of 1-methyl-4-phenyl-1,2,3,5-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain. J Neurochem 48: 1787–1793Google Scholar
  10. Mizuno Y, Suzuki K, Sone N, Saitoh T (1987d) Inhibition of ATP synthesis by 1-methyl-4-phenylpyridinium ion (MPP+) in isolated mitochondria from mouse brain. Neurosci Lett 81:204–208Google Scholar
  11. Mizuno Y, Sone N, Suzuki K, Saitoh T (1988a) Studies on the toxicity of 1-methyl-4-phenylpyridinium ion (MPP+) against mitochondria of mouse brain. J Neurol Sci 86: 97–110Google Scholar
  12. Mizuno Y, Suzuki K, Sone N, Saitoh T (1988b) Inhibition of mitochondrial respiration by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain in vivo. Neurosci Lett 91: 349–353Google Scholar
  13. Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y (1989) Deficiencies in Complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 163: 1450–1455Google Scholar
  14. Mizuno Y, Suzuki K, Ohta S (1990) Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson's disease. J Neurol Sci 96: 49–57Google Scholar
  15. Nagatsu T, Yoshida M (1988) An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions. Neurosci Lett 87: 178–182Google Scholar
  16. Naoi M, Matsuura S, Parvez H, Takahashi T, Hirata Y, Minami M, Nagatsu T (1989) Oxidation of N-methyl-1,2,3,4-tetrahydroisoquinoline into N-methyl-isoquinolinium ion by monoamine oxidase. J Neurochem 52:653–655Google Scholar
  17. Nicklas WJ, Vyas I, Heikkila RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci 36: 2503–2508Google Scholar
  18. Niwa T, Takeda N, Kaneda N, Hashizume Y, Nagatsu T (1987) Presence of tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline in parkinsonian and normal human brains. Biochem Biophys Res Commun 144: 1084–1089Google Scholar
  19. Parkash L (1975) Repair of pyrimidine dimers in nuclear and mitochondrial DNA of yeast irradiated with low doses of ultraviolet light. J Mol Biol 98:781–795Google Scholar
  20. Parker WD, Boyson SJ, Parks JK (1989) Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26: 719–723Google Scholar
  21. Ramsay RR, Salach JI, Singer TP (1986a) Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. Biochem Biophys Res Commun 134: 743–748Google Scholar
  22. Ramsay RR, Salach JI, Dadgar J, Singer TP (1986b) Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic Parkinsonism. Biochem Biophys Res Commun 135: 269–275Google Scholar
  23. Ramsay RR, Singer TP (1986c) Energy dependent uptake of N-methyl-4-phenyl-pyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J Biol Chem 261: 7585–7587Google Scholar
  24. Richter C, Park JW, Ames BN (1988) Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Natl Acad Sci USA 85: 6465–6467Google Scholar
  25. Schapira AHV, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (1989) Mitochondrial complex I deficiency in Parkinson's disease. Lancet i: 1269Google Scholar
  26. Schapira AHV, Cooper JM, Dexter D, Clark JM, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54: 823–827Google Scholar
  27. Suzuki K, Mizuno Y, Yoshida M (1989) Selective inhibition of Complex I of the brain electron transport system by tetrahydroisoquinoline. Biochem Biophys Res Commun 162: 1541–1545Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • H. Yoshino
    • 1
  • Y. Nakagawa-Hattori
    • 1
  • T. Kondo
    • 1
  • Y. Mizuno
    • 1
  1. 1.Department of NeurologyJuntendo University School of MedicineTokyoJapan

Personalised recommendations